Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Cash from Operations (2016 - 2025)

United Therapeutics' Cash from Operations history spans 17 years, with the latest figure at 346200000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 1.47% year-over-year to 346200000.0; the TTM value through Dec 2025 reached 1561200000.0, up 17.64%, while the annual FY2025 figure was 1561200000.0, 17.64% up from the prior year.
  • Cash from Operations for Q4 2025 was 346200000.0 at United Therapeutics, down from 562100000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 562100000.0 in Q3 2025 and bottomed at 89800000.0 in Q1 2021.
  • The 5-year median for Cash from Operations is 245400000.0 (2022), against an average of 263350000.0.
  • The largest annual shift saw Cash from Operations tumbled 58.15% in 2021 before it skyrocketed 221.49% in 2022.
  • A 5-year view of Cash from Operations shows it stood at 174600000.0 in 2021, then fell by 26.58% to 128200000.0 in 2022, then grew by 17.55% to 150700000.0 in 2023, then skyrocketed by 126.41% to 341200000.0 in 2024, then rose by 1.47% to 346200000.0 in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Cash from Operations are 346200000.0 (Q4 2025), 562100000.0 (Q3 2025), and 191700000.0 (Q2 2025).